Human West Nile Virus Neuroinvasive Disease in Texas, 2003 Epidemic: Regional Differences

2006 ◽  
Vol 16 (10) ◽  
pp. 749-755 ◽  
Author(s):  
Ronald D. Warner ◽  
Robert C. Kimbrough ◽  
James L. Alexander ◽  
J. Rush Pierce ◽  
Tigi Ward ◽  
...  
2018 ◽  
Vol 23 (43) ◽  
Author(s):  
Stephan W. Aberle ◽  
Jolanta Kolodziejek ◽  
Christof Jungbauer ◽  
Karin Stiasny ◽  
Judith H. Aberle ◽  
...  

Between 28 June and 17 September 2018, 27 cases of human West Nile virus infections were recorded in Austria; four cases of West Nile neuroinvasive disease, 11 cases of West Nile fever, six infections detected by blood donation screening and six imported cases. In addition, 18 cases of human Usutu virus infections (all blood donors) were recorded. This is the highest number of annual infections recorded in Austria since the introduction of both viruses.


2009 ◽  
Vol 14 (44) ◽  
Author(s):  
L Barzon ◽  
E Franchin ◽  
L Squarzon ◽  
E Lavezzo ◽  
S Toppo ◽  
...  

In 2009, six new human cases of West Nile neuroinvasive disease (WNND) were identified in Veneto region, following the six cases already reported in 2008. A human West Nile virus (WNV) isolate was obtained for the first time from an asymptomatic blood donor. Whole genome sequence of the human WNV isolate showed close phylogenetic relatedness to the Italy-1998-WNV strain and to other WNV strains recently isolated in Europe, with the new acquisition of the NS3-Thr249Pro mutation, a trait associated with avian virulence, increased virus transmission, and the occurrence of outbreaks in humans.


Viruses ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 458 ◽  
Author(s):  
Monia Pacenti ◽  
Alessandro Sinigaglia ◽  
Elisa Franchin ◽  
Silvana Pagni ◽  
Enrico Lavezzo ◽  
...  

West Nile virus (WNV) lineage 2 is expanding and causing large outbreaks in Europe. In this study, we analyzed the epidemiological, clinical, and virological features of WNV lineage 2 infection during the large outbreak that occurred in northern Italy in 2018. The study population included 86 patients with neuroinvasive disease (WNND), 307 with fever (WNF), and 34 blood donors. Phylogenetic analysis of WNV full genome sequences from patients’ samples showed that the virus belonged to the widespread central/southern European clade of WNV lineage 2 and was circulating in the area at least since 2014. The incidence of WNND and WNF progressively increased with age and was higher in males than in females. Among WNND patients, the case fatality rate was 22%. About 70% of blood donors reported symptoms during follow-up. Within the first week after symptom onset, WNV RNA was detectable in the blood or urine of 80% of patients, while 20% and 40% of WNND and WNF patients, respectively, were WNV IgM-seronegative. In CSF samples of WNND patients, WNV RNA was typically detectable when WNV IgM antibodies were absent. Blunted or no WNV IgM response and high WNV IgG levels were observed in seven patients with previous flavivirus immunity.


2020 ◽  
Vol 25 (46) ◽  
Author(s):  
Danique RM Vlaskamp ◽  
Steven FT Thijsen ◽  
Johan Reimerink ◽  
Pieter Hilkens ◽  
Willem H Bouvy ◽  
...  

In October 2020, the first case of autochthonous West Nile virus neuroinvasive disease was diagnosed in the Netherlands with a presumed infection in the last week of August. Investigations revealed five more cases of local West Nile virus (WNV) infection. The cases resided in a region where WNV was detected in a bird and mosquitoes in August 2020. Molecular analysis was successful for two cases and identified the presence of WNV lineage 2.


2018 ◽  
Vol 8 (2) ◽  
Author(s):  
Alyx B Porter ◽  
Akanksha Sharma ◽  
Marie F Grill ◽  
Scott Spritzer ◽  
A Arturo Leis ◽  
...  

Pathogens ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 1073
Author(s):  
Juan-Carlos Saiz

West Nile virus (WNV) is a widely distributed enveloped flavivirus transmitted by mosquitoes, which main hosts are birds. The virus sporadically infects equids and humans with serious economic and health consequences, as infected individuals can develop a severe neuroinvasive disease that can even lead to death. Nowadays, no WNV-specific therapy is available and vaccines are only licensed for use in horses but not for humans. While several methodologies for WNV vaccine development have been successfully applied and have contributed to significantly reducing its incidence in horses in the US, none have progressed to phase III clinical trials in humans. This review addresses the status of WNV vaccines for horses, birds, and humans, summarizing and discussing the challenges they face for their clinical advance and their introduction to the market.


2007 ◽  
Vol 13 (11) ◽  
pp. 1788-1790 ◽  
Author(s):  
Jennifer L. Patnaik ◽  
Lara Juliusson ◽  
Richard L. Vogt

Sign in / Sign up

Export Citation Format

Share Document